Wishing you joy and hope this holiday season

All of us at the Hepatitis B Foundation send our heartfelt wishes for a joyful holiday season to you and your loved ones. The holidays remind us of the strength found in community, compassion and resilience. We are truly grateful for your unwavering support in our mission to improve the lives of those affected by hepatitis B. While this year brought significant challenges, our commitment remains steadfast, and we will continue to persevere.

The Hepatitis B Foundation responds to advisory panel’s vote

against the universal hepatitis B birth dose 

Following a vote against the hepatitis B birth dose vaccination by an advisory committee to the U.S. government, the Hepatitis B Foundation issued a strong protest, warning that the change will lead to preventable infections, liver cancer cases and deaths. Our organization stressed that decades of evidence clearly show the universal birth dose is the safest and most effective way to protect infants, and that delaying or reducing doses has no scientific basis and risks creating confusion among parents and providers.

Please read the full press release here.

The Blumberg family reacts to the advisory panel's action 

The family of Dr. Baruch Blumberg, the Nobel Laureate who discovered the hepatitis B virus and developed the first vaccine against it, has spoken up strongly against the vote by the Advisory Committee on Immunization Practices (ACIP).


"We are appalled by the decision of the CDC's vaccine advisory panel to officially recommend an alteration to the well-established protocols of the infant dose of the vaccine," they wrote.


The statement goes on to say, "The panel's decision flies in the face of more than 60 years of established research and 40 years of global vaccination rollout that has proven both the safety and efficacy of the hepatitis B vaccine."


Please read the Blumberg family's full statement here.

New analysis warns: Delaying the hepatitis B

birth dose could cost lives and billions

A new analysis released in partnership with HepVu, the Hepatitis B Foundation, and the National Viral Hepatitis Roundtable highlights the serious public health and financial consequences of delaying the hepatitis B birth-dose vaccine in the U.S. Using a model based on 2024 U.S. births, researchers found that even short delays leave infants vulnerable during the period when they are most likely to develop chronic, lifelong infection.


Researchers emphasize that these outcomes are predictable—and preventable. Evidence shows that infants who receive the vaccine at birth are more likely to complete the full series, giving them the durable protection they need.


Delays don’t just raise infection rates. They also drive significant increases in chronic hepatitis B, cirrhosis, liver cancer and hepatitis B–related deaths—especially among infants born to mothers who were not screened during pregnancy. The economic toll could be over $3 billion in additional healthcare costs.


Advocates stress that the birth dose and maternal screening work best as a combined prevention strategy. The new data is clear: delaying the hep B birth dose vaccine threatens decades of progress toward eliminating hepatitis B.

New visual summaries of the analysis are now available on HepVu.org and can be shared with your network.

The Foundation partners with the Children's Hospital of Philadelphia

in support of the hepatitis B vaccine

The Hepatitis B Foundation has partnered with the Vaccine Education Center at the Children's Hospital of Philadelphia to create an informative video series designed to help you educate your community. Please share the videos widely!

Featured #BtheVoice storytellers

In this month’s spotlight, four powerful stories highlight the importance of hepatitis B testing, vaccination and community support.


  • Susan describes learning she had hepatitis B during a government screening program and later realizing the seriousness of the disease, finding hope through proper care even as treatment costs remain challenging.
  • In Nigeria, public health advocate Taoheedah shares how diagnosing a pregnant woman with hep B inspired her own testing, vaccination and her founding of the “Health for All Initiative for Community Health.
  • Solomon recounts the stigma and trauma he faced after his 2023 diagnosis but urges others to get tested and vaccinated so they can protect themselves early.
  • Richard reflects on his diagnosis, emphasizing how education, screening and healthy habits helped him move forward and encouraging others to stay strong despite discrimination.


Together, their experiences underscore a shared message: hepatitis B is preventable and manageable. It is not a barrier to living a full and hopeful life.

Please support our work❤️

Hepatitis B is in the spotlight more than ever. The Hepatitis B Foundation and Blumberg Institute are concerned with false narratives being shared about the vaccine.


We're providing you with the facts about the hepatitis B vaccine (birth dose) so that you can help us protect the next generation, enabling them to live in a world free of hepatitis B, hepatitis D and related liver cancer.


Together, we can make a difference. Please donate today.

Hep B United virtual mini-summit recordings

The 2025 Hep B United Virtual Mini-Summit video recordings and slides are available here.


The two-day online event featured partner organizations, advocates and community leaders who gathered to share stories, strategies and support across the hepatitis B spectrum. The recordings include interactive sessions, cultural networking spaces and food recipe videos that celebrate the rich diversity of our communities.

The 2025 Bruce Witte Lecture recording

Prof. Man-Fung Yuen, J.P., MBBS, MD, PhD, DSc. delivered his lecture,

"HBV: A 60-year journey through history, virology, biomarkers,

disease course and treatment,” on Nov. 12

(L-R): Joan Block, Dr. Timothy Block, Jan Witte, Dr. Man-Fung Yuen, Dr. Chari Cohen and Dr. Ju-Tao Guo

Prof. Yuen is a Chair Professor at The University of Hong Kong, Chief , Gastroenterology and Hepatology at Queen Mary Hospital, and an internationally recognized authority on hepatitis B. With more than 630 publications in top medical journals and over 360 lectures worldwide, his groundbreaking work has shaped the global understanding of hepatitis B, C and liver cancer.


You can learn more about Prof. Yuen here.

New blog | Beyond the Liver:

The broader impact of living with chronic hepatitis B

New research is revealing that chronic hepatitis B affects far more than the liver. While hep B is well known as a leading cause of cirrhosis and liver cancer, studies now show it can also raise the risk of cancers in other parts of the body. Researchers have found that HBV can be present in organs like the kidneys and pancreas, where long-term inflammation may contribute to cancer development and other serious conditions such as kidney disease and blood disorders. Please read the full blog here.

A new episode of our podcast is now live!

From exposure to empowerment: Bruno’s journey with hepatitis B

In this episode, Bright and Anousha speak with Bruno D’Amato, a hepatitis B advocate whose diagnosis came decades after an unexpected hospital exposure.


Symptom-free for years, Bruno’s routine tests revealed liver fibrosis, prompting life-changing treatment. He shares his journey from silent infection to healing and the importance of regular monitoring, self-care and hope. 


Please listen to the podcast here.

Bruno, #justB storyteller

The Foundation leads sessions at AASLD:

The 2025 Liver Meeting in Washington, D.C.

(L-R) Dr. Robert Gish, Dr. Chari Cohen, Dr. Donna Evon, Dr. Su Wang, Wendy Lo and Dr. Zobair Younossi

The AASLD's Liver Meeting in Washington, D.C., Nov. 7–11, brought together the global hepatology community to explore the newest advances in liver disease research, clinical care and patient-centered innovation. At this year’s conference, Foundation President Dr. Chari Cohen joined colleagues to present “Assessing and Addressing Quality of Life and Patient-Reported Outcomes: Creating Shared Decision-Making for Hepatitis B Management and Treatment,” reinforcing our commitment to elevating patient voices and ensuring that their experiences guide better, more collaborative care.

Dr. Catherine Freeland presenting a Poster of Distinction, "Comprehensive hepatitis B perinatal prevention interventions in Delta State, Nigeria," which she produced with Prince Okinedo.

Dr. Timothy Block, co-founder of our organization (above), and Wendy Lo (below at the podium), one of our #justB storytellers and patient advocate, participated in a panel discussion.

Journal article of the month

Vaccination: A remarkable success story that must continue. 


Gastroenterology. 2025 Nov. 13:S0016-5085(25)06482-0. doi: 10.1053/j.gastro.2025.10.295. Epub ahead of print. PMID: 41241364.

Click here to access the article.


Lok AS, Cohen C, Chang MH, Ward JW, et al

In their conclusion, the authors wrote "Universal HepB birth dose vaccination regardless of maternal HBsAg status is the most effective as well as the most cost-effective strategy in eliminating HBV infection."


They point out that "Newborns and infants are those at highest risk of chronic HBV infection. Delaying the first dose of HepB vaccine even by a few days exposes the infants to increased risk of developing lifelong infection, chronic liver disease, and premature death." The authors write that the universal birth dose and infant hepatitis B vaccination is necessary to ensure protection of children from HBV infection and support the elimination of the disease as a health threat among vaccinated communities in the U.S. and globally.

Learn more about our research and education programs at www.hepb.org

The Hepatitis B Foundation is a global nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Our commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community and the general public.

Facebook  Twitter  Instagram  Youtube